Effect of CytoregR on Biomarkers in B16-F10 Murine Melanoma

Weston, Florida August 2, 2004. Cytorex Biosciences Inc. (Cytorex), a privately owned Biotechnology company of Weston , Florida presented at the Drug Discovery Conference on August 9, 2004.

They displayed a poster titled: “Effect of Cytoreg® on Biomarkers in B16-F10 Murine Melanoma”. The topic is the result of a pilot study performed by Dr. Manzur Hassanhi, MD, Senior Research Scientist of Cytorex Biosciences Inc., and Dr. Elzbieta Izbicka of the Institute of Drug Development (IDD), San Antonio , Texas . Over 300 submitted poster abstracts were reviewed by a poster review committee to determine the 150 posters to be displayed at this year's conference. Poster topic categories were chosen to mirror the topics covered in conference sessions.

This coordinated effort enabled attendees to easily locate the posters that relate to their areas of interest. All posters were  located inside the exhibit hall.

 “Cytoreg® is a novel anticancer drug candidate which uses Hydrofluoric and Sulfuric acids as active compounds. Upon completion of an in vivo study performed under a separate agreement, formalin preserved lung tissue with B16-F10 metastases was provided for biomarker analysis. Quantitative analysis of Bcl-2, Bax, Smac/Diablo, Survivin, Raf-1, and (P) Raf-1 was performed in thin sections from three representative tumor metastases selected from the drug treatment group (.654 mg/mouse, p.o., qd x 5 to end) and the corresponding control vehicle. Two biomarkers (Bcl-2, Smac/Diablo) were below detection limits. Cytoreg® induced some down regulation in Bax. Biomarkers levels of Survivin and the (P) Raf-1/Raf-1 ratios were decreased in the Cytoreg® treatment group. These finding are consistent with the pro-apoptotic activity of the drug and the ability of Cytoreg® to interfere with tumor signaling pathways in B16-F10 lung metastases” according to Dr. Elzbieta Izbicka, Head of the Molecular Targets Laboratory of IDD.

About Cytorex Biosciences:

Cytorex Biosciences Inc is a privately owned Biotechnology company in Weston , Florida involved in the development of Cytoreg® and CytoregUNO™, the company's novel therapeutic agents against cancer, currently in pre-clinical phase. The company is in the initial stage of a private offering. This is not to be construed as a solicitation to offer or sell securities.

For more information on Cytorex Biosciences, visit the company’s website at www.cytorex.com, or contact in the USA , Carlos M. Garcia, COO (954-993-4941).

Email: coo@cytorex.com